Tasquinimod in the treatment of castrate-resistant prostate cancer – current status and future prospects by Amit R. Mehta, Andrew J. Armstrong

Get full text

Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T? by Rhonda L. Bitting, Andrew J. Armstrong, Daniel J. George

Get full text

A synthetic lethal screen for Snail-induced enzalutamide resistance identifies JAK/STAT signaling as a therapeutic vulnerability in prostate cancer by Kathryn E. Ware, Kathryn E. Ware, Beatrice C. Thomas, Pelumi D. Olawuni, Pelumi D. Olawuni, Maya U. Sheth, Maya U. Sheth, Nathan Hawkey, Nathan Hawkey, M. Yeshwanth, Brian C. Miller, Katherine J. Vietor, Mohit Kumar Jolly, So Young Kim, Andrew J. Armstrong, Andrew J. Armstrong, Andrew J. Armstrong, Jason A. Somarelli, Jason A. Somarelli

Get full text

Analysis of immune subtypes across the epithelial-mesenchymal plasticity spectrum by Priyanka Chakraborty, Emily L. Chen, Isabelle McMullen, Andrew J. Armstrong, Mohit Kumar Jolly, Jason A. Somarelli

Get full text

Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond by Jason Zhu, Andrew J. Armstrong, Terence W. Friedlander, Won Kim, Sumanta K. Pal, Daniel J. George, Tian Zhang

Get full text

Novel therapies are changing treatment paradigms in metastatic prostate cancer by Eric Powers, Georgia Sofia Karachaliou, Chester Kao, Michael R. Harrison, Christopher J. Hoimes, Daniel J. George, Andrew J. Armstrong, Tian Zhang

Get full text

Emergent dynamics of underlying regulatory network links EMT and androgen receptor-dependent resistance in prostate cancer by Rashi Jindal, Abheepsa Nanda, Maalavika Pillai, Kathryn E. Ware, Divyoj Singh, Manas Sehgal, Andrew J. Armstrong, Jason A. Somarelli, Mohit Kumar Jolly

Get full text

Rewiring of the N-Glycome with prostate cancer progression and therapy resistance by William Butler, Colin McDowell, Qing Yang, Yiping He, Yue Zhao, J. Spencer Hauck, Yinglu Zhou, Hong Zhang, Andrew J. Armstrong, Daniel J. George, Richard Drake, Jiaoti Huang

Get full text

The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials by Bertrand Tombal, Arnulf Stenzl, David Cella, Yohann Loriot, Andrew J. Armstrong, Karim Fizazi, Tomasz Beer, Cora N. Sternberg, Maha Hussain, Cristina Ivanescu, Arijit Ganguli, Krishnan Ramaswamy, Fred Saad

Get full text

RB1-deficient prostate tumor growth and metastasis are vulnerable to ferroptosis induction via the E2F/ACSL4 axis by Mu-En Wang, Jiaqi Chen, Yi Lu, Alyssa R. Bawcom, Jinjin Wu, Jianhong Ou, John M. Asara, Andrew J. Armstrong, Qianben Wang, Lei Li, Yuzhuo Wang, Jiaoti Huang, Ming Chen

Get full text

Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer by Matthew D. Tucker, Jason Zhu, Daniele Marin, Rajan T. Gupta, Santosh Gupta, William R. Berry, Sundhar Ramalingam, Tian Zhang, Michael Harrison, Yuan Wu, Patrick Healy, Stacey Lisi, Daniel J. George, Andrew J. Armstrong

Get full text

LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types by Ramy Sedhom, Santosh Gupta, Yuan Wu, Jason Zhu, Daniele Marin, Michael R Harrison, Landon C Brown, Matthew D Tucker, Eric B Schwartz, Chester Kao, Matthew K Labriola, Rajan T Gupta, Daniel J George, Emmanuel S Antonarakis, Andrew J Armstrong

Get full text

Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer by Tian Zhang, Anika Agarwal, R. Garland Almquist, Daniella Runyambo, Sally Park, Elizabeth Bronson, Rengasamy Boominathan, Chandra Rao, Monika Anand, Taofik Oyekunle, Patrick Healy, Megan A. McNamara, Kathryn Ware, Jason A. Somarelli, Daniel J. George, Andrew J. Armstrong

Get full text

Initial Longitudinal Outcomes of Risk-Stratified Men in Their Forties Screened for Prostate Cancer Following Implementation of a Baseline Prostate-Specific Antigen by Zoe D. Michael, Srinath Kotamarti, Rohith Arcot, Kostantinos Morris, Anand Shah, John Anderson, Andrew J. Armstrong, Rajan T. Gupta, Steven Patierno, Nadine J. Barrett, Daniel J. George, Glenn M. Preminger, Judd W. Moul, Kevin C. Oeffinger, Kevin Shah, Thomas J. Polascik

Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma by Matthew D. Tucker, Landon C. Brown, Yu-Wei Chen, Chester Kao, Nathan Hirshman, Emily N. Kinsey, Kristin K. Ancell, Kathryn E. Beckermann, Nancy B. Davis, Renee McAlister, Kerry Schaffer, Andrew J. Armstrong, Michael R. Harrison, Daniel J. George, W. Kimryn Rathmell, Brian I. Rini, Tian Zhang

Get full text

Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer. by Andrew J Armstrong, Santosh Gupta, Patrick Healy, Gabor Kemeny, Beth Leith, Michael R Zalutsky, Charles Spritzer, Catrin Davies, Colin Rothwell, Kathryn Ware, Jason A Somarelli, Kris Wood, Thomas Ribar, Paraskevi Giannakakou, Jiaren Zhang, Drew Gerber, Monika Anand, Wen-Chi Foo, Susan Halabi, Simon G Gregory, Daniel J George

Get full text

The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metas... by Yu-Wei Chen, Matthew D. Tucker, Landon C. Brown, Hesham A. Yasin, Kristin K. Ancell, Andrew J. Armstrong, Kathryn E. Beckermann, Nancy B. Davis, Michael R. Harrison, Elizabeth G. Kaiser, Renee K. McAlister, Kerry R. Schaffer, Deborah E. Wallace, Daniel J. George, W. Kimryn Rathmell, Brian I. Rini, Tian Zhang

Get full text

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial by Jun Li, Stefanie Zschäbitz, Daniel P Petrylak, Margitta Retz, Prabhu Bhagavatheeswaran, Marc-Oliver Grimm, Jose Perez-Gracia, Gwenaelle Gravis, Karim Fizazi, Jeffrey C Goh, Mauricio Burotto, Daniel Castellano, Fred Saad, Andrew J Armstrong, HAKIM MAHAMMEDI, Russell K Pachynski, Louis Lacombe, Diogo Assed Bastos, Steven L McCune, Juan Carlos Vázquez Limón, Edmond M Kwan, Aude Fléchon, David R Shaffer, Neha P Amin, Keziban Ünsal-Kaçmaz, Xuya Wang, Andrea Loehr

Get full text

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy by Karen A. Autio, Emmanuel S. Antonarakis, Tina M. Mayer, Daniel H. Shevrin, Mark N. Stein, Ulka N. Vaishampayan, Michael J. Morris, Susan F. Slovin, Elisabeth I. Heath, Scott T. Tagawa, Dana E. Rathkopf, Matthew I. Milowsky, Michael R. Harrison, Tomasz M. Beer, Arjun V. Balar, Andrew J. Armstrong, Daniel J. George, Channing J. Paller, Arlyn Apollo, Daniel C. Danila, Julie N. Graff, Luke Nordquist, Erica S. Dayan Cohn, Kin Tse, Nicole A. Schreiber, Glenn Heller, Howard I. Scher

Get full text

A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer by Shuang G. Zhao, Jamie M. Sperger, Jennifer L. Schehr, Rana R. McKay, Hamid Emamekhoo, Anupama Singh, Zachery D. Schultz, Rory M. Bade, Charlotte N. Stahlfeld, Cole S. Gilsdorf, Camila I. Hernandez, Serena K. Wolfe, Richel D. Mayberry, Hannah M. Krause, Matt Bootsma, Kyle T. Helzer, Nicholas Rydzewski, Hamza Bakhtiar, Yue Shi, Grace Blitzer, Christos E. Kyriakopoulos, David Kosoff, Xiao X. Wei, John Floberg, Nan Sethakorn, Marina Sharifi, Paul M. Harari, Wei Huang, Himisha Beltran, Toni K. Choueiri, Howard I. Scher, Dana E. Rathkopf, Susan Halabi, Andrew J. Armstrong, David J. Beebe, Menggang Yu, Kaitlin E. Sundling, Mary-Ellen Taplin, Joshua M. Lang

Get full text